EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

Pentoxifylline as a Novel Add-on Therapy for Major Depressive Disorder in Adult Patients: A Randomized, Double-Blind, Placebo-Controlled Trial

Talar A Merza Mohammad, Tavgah A Merza Mohammad, Dyar M Salman, Halmat M Jaafar

Pharmacopsychiatry · 01.07.2024 · 57 (04) · 205-214

DOI: 10.1055/a-2291-7204 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Pharmacopsychiatry, erschienen am 01.07.2024. Verfasst von Talar A Merza Mohammad und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacy, College of Pharmacy, Hawler Medical University, Kurdistan Region-Erbil, Iraq. Hauptthemen laut MEDLINE: Major Depressive Disorder, Pentoxifylline, Citalopram, Drug Therapy, Combination. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 67 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Evidence indicates an association between immune dysregulation and major depressive disorder (MDD). Pentoxifylline (PTX), a phosphodiesterase inhibitor, has been shown to reduce pro-inflammatory activities. The aim of this study was to evaluate changes in depressive symptoms and pro-inflammatory markers after administration of PTX as an adjunctive agent to citalopram in patients with MDD.

Methods

One hundred patients were randomly assigned to either citalopram (20 mg/day) plus placebo (twice daily) (n=50) or citalopram (20 mg/day) plus PTX (400 mg) (twice daily) (n=50). The Hamilton Depression Rating Scale-17 (HAM-D-17) scores at baseline, weeks 2, 4, 6, 8, 10, and 12 and serum levels of interleukin1-β (IL-1-β), tumor necrosis factor-α, C-reactive protein, IL-6, serotonin, IL-10, and brain-derived neurotrophic factor (BDNF) at baseline and week 12 were evaluated.

Results

HAM-D-17 score in the PTX group significantly reduced in comparison to the control group after weeks 4, 6, 8,10, and 12 ((LSMD): − 2.193, p=0.021; − 2.597, p=0.036; − 2.916, p=0.019; − 4.336, p=0.005; and − 4.087, p=0.008, respectively). Patients who received PTX had a better response (83%) and remission rate (79%) compared to the placebo group (49% and 40%, p=0.006 and p=0.01, respectively). Moreover, the reduction in serum concentrations of pro-inflammatory factors and increase in serotonin and BDNF in the PTX group was significantly greater than in the placebo group (p

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Major Depressive DisorderPentoxifyllineCitalopramDrug Therapy, CombinationHumansMaleFemaleDouble-Blind MethodAdultMiddle AgedTreatment OutcomeBrain-Derived Neurotrophic FactorPsychiatric Status Rating ScalesC-Reactive ProteinYoung AdultSerotoninAntidepressive AgentsPhosphodiesterase Inhibitors

Substanzen

PentoxifyllineCitalopramBrain-Derived Neurotrophic FactorC-Reactive ProteinSerotoninAntidepressive AgentsPhosphodiesterase Inhibitors

Autor:innen und Institutionen

  • Department of Clinical Pharmacy, College of Pharmacy, Hawler Medical University, Kurdistan Region-Erbil, Iraq.
  • University of Sulaimani, College of Nursing, Department of Community Health Nursing, Kurdistan Region-Erbil, Iraq.
  • Tishk International University, Faculty of Pharmacy, Kurdistan Region-Erbil, Iraq.

Zitieren

APA

Merza Mohammad, T. A., Merza Mohammad, T. A., Salman, D. M., & Jaafar, H. M. (2024). Pentoxifylline as a Novel Add-on Therapy for Major Depressive Disorder in Adult Patients: A Randomized, Double-Blind, Placebo-Controlled Trial. Pharmacopsychiatry, 57(04), 205-214. https://doi.org/10.1055/a-2291-7204

Vancouver

Merza Mohammad TA, Merza Mohammad TA, Salman DM, Jaafar HM. Pentoxifylline as a Novel Add-on Therapy for Major Depressive Disorder in Adult Patients: A Randomized, Double-Blind, Placebo-Controlled Trial. Pharmacopsychiatry. 2024;57(04):205-214. doi:10.1055/a-2291-7204

BibTeX
@article{MerzaMohammad2024,
  author = {Merza Mohammad, Talar A and Merza Mohammad, Tavgah A and Salman, Dyar M and Jaafar, Halmat M},
  title = {Pentoxifylline as a Novel Add-on Therapy for Major Depressive Disorder in Adult Patients: A Randomized, Double-Blind, Placebo-Controlled Trial},
  journal = {Pharmacopsychiatry},
  year = {2024},
  volume = {57},
  number = {04},
  pages = {205--214},
  doi = {10.1055/a-2291-7204}
}
Kostenlos starten →